Cargando…

Germline genetic variation and predicting immune checkpoint inhibitor induced toxicity

Immune checkpoint inhibitor (ICI) therapy has revolutionised the treatment of various cancer types. ICIs reinstate T-cell function to elicit an anti-cancer immune response. The resulting immune response can however have off-target effects which manifest as autoimmune type serious immune-related adve...

Descripción completa

Detalles Bibliográficos
Autores principales:	Chin, Ik Shin, Khan, Aman, Olsson-Brown, Anna, Papa, Sophie, Middleton, Gary, Palles, Claire
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789157/ https://www.ncbi.nlm.nih.gov/pubmed/36564402 http://dx.doi.org/10.1038/s41525-022-00345-6

Ejemplares similares

IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma
por: Taylor, Chelsea A., et al.
Publicado: (2022)

Germline biomarkers predict toxicity to anti-PD1/PDL1 checkpoint therapy
por: Weidhaas, Joanne, et al.
Publicado: (2022)

Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade
por: Patel, Akshay J., et al.
Publicado: (2022)

ToxNav germline genetic testing and PROMinet digital mobile application toxicity monitoring: Results of a prospective single‐center clinical utility study—PRECISE study
por: Lee, Lennard Y. W., et al.
Publicado: (2019)

Impact of age on the toxicity of immune checkpoint inhibition
por: Samani, Amit, et al.
Publicado: (2020)

Germline genetic variants are associated with development of insulin-dependent diabetes in cancer patients treated with immune checkpoint inhibitors
por: Caulfield, Jasmine I, et al.
Publicado: (2023)

Management of Immune Checkpoint Inhibitor Toxicities
por: Durrechou, Quentin, et al.
Publicado: (2020)

Toxicities associated with checkpoint inhibitors—an overview
por: Spiers, Laura, et al.
Publicado: (2019)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

NLRC5 germline variants as potential pharmacogenomic markers for immune checkpoint inhibitors
por: Meng, Xiang-Yu
Publicado: (2023)

Does immune checkpoint inhibitor therapy increase the frequency of adverse reactions to concomitant medications?
por: Hammond, Sean, et al.
Publicado: (2022)

Toxicity of Immune-Checkpoint Inhibitors in Hematological Malignancies
por: Hradska, Katarina, et al.
Publicado: (2021)

Overcoming the cardiac toxicities of cancer therapy immune checkpoint inhibitors
por: Irabor, Omoruyi Credit, et al.
Publicado: (2022)

Setting the scene – a future ‘epidemic’ of immune-related adverse events in association with checkpoint inhibitor therapy
por: Bermudez, Maria V, et al.
Publicado: (2019)

Predictive Biomarkers of Immune Checkpoint Inhibitors-Related Toxicities
por: Xu, Ya, et al.
Publicado: (2020)

Cutaneous Toxicities of Immune Checkpoint Inhibitors: The Role of the Dermatologist
por: Tattersall, Ian William, et al.
Publicado: (2020)

Immune-checkpoint inhibitors: long-term implications of toxicity
por: Johnson, Douglas B., et al.
Publicado: (2022)

Frailty and checkpoint inhibitor toxicity in older patients with melanoma
por: Bruijnen, Cheryl P., et al.
Publicado: (2022)

Imaging features of toxicities associated with immune checkpoint inhibitors
por: Gosangi, Babina, et al.
Publicado: (2022)

Management of pulmonary toxicity associated with immune checkpoint inhibitors
por: Delaunay, Myriam, et al.
Publicado: (2019)

Imaging assessment of toxicity related to immune checkpoint inhibitors
por: Berz, Antonia M., et al.
Publicado: (2023)

Endocrine toxicity of immune checkpoint inhibitors: essential crosstalk between endocrinologists and oncologists
por: Illouz, Frédéric, et al.
Publicado: (2017)

Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach
por: Khan, Zia, et al.
Publicado: (2019)

Collision of germline POLE and PMS2 variants in a young patient treated with immune checkpoint inhibitors
por: Berrino, Enrico, et al.
Publicado: (2022)

Imaging Features of Toxicities by Immune Checkpoint Inhibitors in Cancer Therapy
por: Widmann, Gerlig, et al.
Publicado: (2017)

Campylobacteriosis following immunosuppression for immune checkpoint inhibitor-related toxicity
por: Lee, Karla A, et al.
Publicado: (2020)

Immune Checkpoint Inhibitor-Related Pulmonary Toxicity: Focus on Nivolumab
por: Bukamur, Hazim, et al.
Publicado: (2020)

Impact of the gut microbiota on immune checkpoint inhibitor-associated toxicities
por: Pezo, Rossanna C., et al.
Publicado: (2019)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: Clinical Risk Factors
por: Pirozzi, Flora, et al.
Publicado: (2021)

Neurologic Toxicity of Immune Checkpoint Inhibitors: A Review of Literature
por: Albarrán, Víctor, et al.
Publicado: (2022)

Immune Checkpoint Inhibitors and Kidney Toxicity: Advances in Diagnosis and Management
por: Seethapathy, Harish, et al.
Publicado: (2021)

Case Report: Cardiac Toxicity Associated With Immune Checkpoint Inhibitors
por: Chen, Ru, et al.
Publicado: (2021)

Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
por: Li, Haoran, et al.
Publicado: (2022)

Immune Checkpoint Inhibitor Rechallenge After Prior Immune Toxicity
por: Bylsma, Sophia, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Infections Simulating Immune Checkpoint Inhibitor Toxicities: Uncommon and Deceptive
por: Gudiol, Carlota, et al.
Publicado: (2022)

Cardiovascular Toxicity of Immune Checkpoint Inhibitors: A Guide for Clinicians
por: Raschi, Emanuel, et al.
Publicado: (2023)

Risk Factors for Immune Checkpoint Inhibitor–Mediated Cardiovascular Toxicities
por: Yousif, Laura I., et al.
Publicado: (2023)

Toxicities associated with immune checkpoint inhibitors: a systematic study
por: Kong, Xiangyi, et al.
Publicado: (2023)

Nivolumab-Induced Toxic Epidermal Necrolysis: Rare but Fatal Complication of Immune Checkpoint Inhibitor Therapy
por: Kim, Michael C, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_e8ntda5r45gr6f8pdj2ktauur2